Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Anbio Biotechnology (NNNN) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Anbio Biotechnology (NNNN), most recent 12 months reported: revenue $8.65M, net income $6.4M. Latest balance sheet on file: liquid cash $11.9M. From SEC filings. Others in In Vitro & In Vivo Diagnostic Substances: MYRIAD GENETICS, INC. · INTELLIA THERAPEUTICS, INC. · Alpha Teknova, Inc. · ImmuCell Corporation · Aspira Women’s Health Inc. · BIOMERICA, INC. · VolitionRx Limited · Insight Molecular Diagnostics Inc.

Stock screener

Watchlist